Publications (51) View all
-
Article: Efficacy and Safety of Leflunomide for the Treatment of BK Virus-Associated Hemorrhagic Cystitis in Allogeneic Hematopoietic Stem Cell Transplantation Recipients.
[show abstract] [hide abstract]
ABSTRACT: BK virus-associated hemorrhagic cystitis (BKV-HC) is a severe complication after allogeneic hematopoietic stem cell transplantation. So far, no specific antiviral drug with proven efficacy has been approved for treating BKV-HC. Leflunomide is an immunosuppressive drug with antiviral activity and has been used in treating BKV-associated nephropathy after renal transplantation. This is the first report on the efficacy and safety of leflunomide in the treatment of BKV-HC. From January 2006 to January 2009, 89 patients received allogeneic hematopoietic stem cell transplantation, and among them, 18 patients were identified as having BKV-HC, with a 20% cumulative incidence. Fourteen patients were treated with oral leflunomide. Three days of 100 mg/day leflunomide was used as loading doses and followed by maintenance doses of 20 mg/day. The urinary BKV-DNA load was monitored weekly by real-time quantitative PCR. The efficacy was evaluated on day 20 after leflunomide treatment. Seven patients (50%) achieved complete remission, 5 patients (35.7%) achieved partial remission, and 2 patients (14.3%) had more than a 1-log reduction in urinary BKV-DNA loads after treatment. During the leflunomide treatment, the graft-versus-host disease of the patients did not progress, and the dosages of the immunosuppressant were reduced simultaneously. One patient discontinued treatment because of intolerable gastrointestinal symptoms. Neutropenia occurred in 2 cases. These preliminary data suggest that leflunomide may be a potentially effective medication for treating BKV-HC without significant toxicity, but evidence supporting its use requires randomized controlled trials.Acta Haematologica 02/2013; 130(1):52-56. · 1.35 Impact Factor -
Article: [Complex hemolytic anemia in one patient.]
Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi 01/2013; 34(1):85. -
Article: Effective Induction Therapy with Subcutaneous Administration of Bortezomib for Newly Diagnosed POEMS Syndrome: A Case Report and a Review of the Literature.
[show abstract] [hide abstract]
ABSTRACT: POEMS syndrome is characterized by polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy and skin changes. Bortezomib is an important component of the chemotherapy regimen associated with multiple myeloma, and has been previously applied to POEMS syndrome. We present a 56-year-old Chinese man who was given subcutaneous administration of bortezomib as part of the BDex (bortezomib-dexamethasone) regimen for his POEMS syndrome. The peripheral neuropathy and laboratory-test results of the patient improved dramatically with 4 cycles of treatment, resulting in a complete response. In addition, the treatment was well tolerated and adequate peripheral blood hematopoietic stem cells were collected for an ensuing autologous stem cell transplant.Acta Haematologica 11/2012; 129(2):101-105. · 1.35 Impact Factor -
Article: [Pulmonary lymphoma with hematogenous disseminated pulmonary tuberculosis: a case report].
Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi 10/2012; 33(10):860. -
Article: [The clinical features, therapeutic effects and prognosis of mantle cell lymphoma].
[show abstract] [hide abstract]
ABSTRACT: To analyze clinical features, therapeutic effects and prognostic factors of patients with mantle cell lymphoma (MCL). Clinical data of 37 MCL patients hospitalized in our hospital from January 2000 to March 2010 were retrospectively analyzed. The median age was 62, with a male predominance. 97.30% of the patients were in Ann Arbor stage III ∼ IV, 54.05% with B symptoms, 64.86% with bone marrow involvement, 29.73% with splenomegaly, 24.32% with lymphocytosis and 51.35% with elevated LDH. Ki-67 was detected in 22 cases, and patients with Ki-67 ≤ 40% accounted for 68.18%. Of 37 cases, the overall response rate (ORR) of rituximab combined with chemotherapy was 92.31%, being higher than those of CHOP (46.15%) and CHOP + IFN (42.86%) regimens. There were statistical differences in the 3-year progression-free survival (PFS) and overall survival (OS) between rituximab + chemotherapy and CHOP or CHOP + interferon regimens (P < 0.05, respectively). Splenomegaly, elevated WBC, lymphocytosis and Ki-67 > 40% were identified as adverse prognostic factors. Most patients with MCL were older adults, with a male predominance and usually had bone marrow involvement and poor prognosis. Rituximab combined with chemotherapy could improve ORR and OS of MCL.Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi 04/2011; 32(4):231-5.
